Anavex Life Sciences Corp (AVXL)

[bas2020]

ALL endpoints WERE met, as stated by the company... thus, it WAS very successful.

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

And the additional data, provided in September, was further evidence of a very successful trial...

• ADCS-Cog and CDR-SB (p < .025) proving further evidence of stat. sig. improvements and trial success.

• Identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization) for AA pathway option.